Inferra AI / Company / BMRN
Biomarin Pharmaceutical Inc.
BMRN · Health Care
Last earnings Aug 6, 2026
Key results
Total revenuequarter
$766 million
Total Revenues Increased Year-over-year to $766 million
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
Enzyme Therapies revenuequarter
6%
Enzyme Therapies revenue grew 6% Y Y in the first quarter, driven by revenue growth for VIMIZIM , NAGLAZYME , and BRINEURA .
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
First Quarter 2026 Financial Highlights Total Revenues for the first quarter of 2026 were $766 million, an increase of $21 million compared to the same period in 2025, primarily driven by timing of large government orders outside the U.
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
GAAP net incomequarter
$106 million
GAAP Net Income for the first quarter of 2026 decreased to $106 million compared to $186 million for the same period in 2025.
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
Revenuequarter
$766,208 thousand
Total revenues 766,208 745,145
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
Research and developmentquarter
$178,796 thousand
Research and development 178,796 158,731
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
Net incomequarter
$105,527 thousand
NET INCOME $ 105,527 $ 185,686
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
EPSquarter
$ 0.54
DILUTED $ 0.54 $ 0.95
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
AI analysis
Q1 2026 · reported May 4, 2026
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · May 4, 2026 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q1 2026 | Prior qtr | Year ago |
|---|---|---|---|
| Total revenue | $766 million | — | — |
| Enzyme Therapies revenue | 6% | — | — |
| GAAP net income | $106 million | — | $186 million |
| Revenue | $766,208 thousand | — | — |
| Research and development | $178,796 thousand | — | — |
| Net income | $105,527 thousand | — | — |
| EPS | $ 0.54 | — | — |
Guidance · company-stated
Direction: Raised
“(415) 455-7558 (650) 374-2803 BioMarin Reports First Quarter 2026 Financial and Operating Results First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growth Rate of 20% Y Y at the Midpoint, and Reflecting the Addition of GALAFOLD and POMBILITI + OPFOLDA to BioMarin s Portfolio Conference Call and Webcast Scheduled Today at 4 30 p.”
“Growth Increased full-year 2026 Total Revenues guidance, accelerating anticipated growth rate to 20% Y Y, as a result of the addition of GALAFOLD for Fabry disease and POMBILITI + OPFOLDA to BioMarin s commercial portfolio.”
“As previously communicated, the acquisition of Amicus is expected to be slightly dilutive to full-year 2026 Non GAAP Diluted EPS historical BioMarin Non-GAAP Diluted EPS guidance is unchanged.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Value Commitment During the first quarter, the company secured financing of approximately $3.7 billion of non-convertible debt to support the Amicus acquisition, achieving favorable pricing across the capital structure.
Non-GAAP Weighted-Average Diluted Shares Outstanding is defined by the company as GAAP Weighted-Average Diluted Shares Outstanding, adjusted to include any common shares issuable under the company s equity plans or convertible debt in periods when they are dilutive under Non-GAAP.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue 0.0% computed from stated figures
Event summary
Biomarin Pharmaceutical Inc. Q1 2026 — Total Revenues Increased Year-over-year to $766 million
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Raised
Revenue: “(415) 455-7558 (650) 374-2803 BioMarin Reports First Quarter 2026 Financial and Operating Results First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growth Rate of 20% Y Y at the Midpoint, and Reflecting the Addition of GALAFOLD and POMBILITI + OPFOLDA to BioMarin s Portfolio Conference Call and Webcast Scheduled Today at 4 30 p.”
Revenue: “Growth Increased full-year 2026 Total Revenues guidance, accelerating anticipated growth rate to 20% Y Y, as a result of the addition of GALAFOLD for Fabry disease and POMBILITI + OPFOLDA to BioMarin s commercial portfolio.”
Revenue — Raised (“Increased”)
“(415) 455-7558 (650) 374-2803 BioMarin Reports First Quarter 2026 Financial and Operating Results First Quarter 2026 Total Revenues Increased Year-over-year to $766 million Increased Full-year 2026 Total Revenues Guidance to between $3.825 billion and $3.925 billion, Representing Accelerated Growth Rate of 20% Y Y at the Midpoint, and Reflecting the Addition of GALAFOLD and POMBILITI + OPFOLDA to BioMarin s Portfolio Conference Call and Webcast Scheduled Today at 4 30 p.”
Revenue — Raised (“Increased”)
“Growth Increased full-year 2026 Total Revenues guidance, accelerating anticipated growth rate to 20% Y Y, as a result of the addition of GALAFOLD for Fabry disease and POMBILITI + OPFOLDA to BioMarin s commercial portfolio.”
EPS — Reiterated (“unchanged”)
“As previously communicated, the acquisition of Amicus is expected to be slightly dilutive to full-year 2026 Non GAAP Diluted EPS historical BioMarin Non-GAAP Diluted EPS guidance is unchanged.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Value Commitment During the first quarter, the company secured financing of approximately $3.7 billion of non-convertible debt to support the Amicus acquisition, achieving favorable pricing across the capital structure.
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
Non-GAAP Weighted-Average Diluted Shares Outstanding is defined by the company as GAAP Weighted-Average Diluted Shares Outstanding, adjusted to include any common shares issuable under the company s equity plans or convertible debt in periods when they are dilutive under Non-GAAP.
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
We have incurred in the past and may in the future incur substantial indebtedness that may decrease our business flexibility, access to capital, and/or increase our borrowing costs, which may adversely affect our operations and financial results.
SEC original ↗Biomarin Pharmaceutical Inc. — 10-Q Quarterly report10-QAug 6, 2026
The total purchase consideration for the acquisition of Amicus was $ 5.3 billion, which consisted of cash consideration paid to former Amicus shareholders, cash payments related to the settlement of equity awards and stock options, the settlement of Amicus outstanding debt, and certain seller transaction costs paid by the Company on behalf of Amicus.
SEC original ↗Biomarin Pharmaceutical Inc. — 10-Q Quarterly report10-QAug 6, 2026
The transaction was financed through a combination of cash on hand and non-convertible debt financing.
SEC original ↗Biomarin Pharmaceutical Inc. — 10-Q Quarterly report10-QAug 6, 2026
In connection with the acquisition, the Company issued $ 850.0 million in aggregate principal amount of 5.5 % senior unsecured notes in February 2026, and obtained senior secured term loan facilities for $ 2.8 billion in aggregate principal in April 2026.
SEC original ↗Biomarin Pharmaceutical Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
Continued underlying patient demand in Q1 for PALYNZIQ was driven by an increase in enrollments and new starts in the under-18-year age group following label expansion in February.
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
The decrease in GAAP Net Income was primarily attributed to the following higher Selling, General Administrative (SG A) spend primarily due to incremental administrative costs related to ongoing support of corporate initiatives and pre-close costs for Amicus acquisition, and higher sales and marketing spend on VOXZOGO, PALYNZIQ and VIMIZIM higher Cost of Sales primarily due to a $31 million charge associated with an unsuccessful process qualification campaign to expand NAGLAZYME manufacturing capabilities 2 higher Research and Development spend to support BMN 401, a late-stage clinical program acquired in the third quarter of 2025 partially offset by revenue growth as mentioned above.
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
3 Forward-Looking Non-GAAP Financial Information BioMarin does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because the company is unable to predict with reasonable certainty the financial impact of changes resulting from its strategic portfolio and business operating model reviews potential future asset impairments gains and losses on investments and other unusual gains and losses without unreasonable effort.
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
Canada Dial-in Number 800-715-9871 Replay Dial-in Number 800-770-2030 International Dial-in Number 646-307-1963 Replay International Dial-in Number 609-800-9909 Conference ID 3424435 Conference ID 3424435 4 About BioMarin BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions.
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
(2) These amounts were included in SG A and represent charges for severance in connection with the company s plan to simplify its organizational design and strategic initiatives in the first quarter of 2026.
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
Risks & headwinds
These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements.
SEC original ↗Biomarin Pharmaceutical Inc. — Earnings release (8-K exhibit)EX-99May 4, 2026
In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
SEC original ↗Biomarin Pharmaceutical Inc. — 10-Q Quarterly report10-QAug 6, 2026
Table of Contents Risk Factors Summary The following is a summary of the principal risks that could adversely affect our business, financial condition, operating results, cash flows or stock price.
SEC original ↗Biomarin Pharmaceutical Inc. — 10-Q Quarterly report10-QAug 6, 2026
Changes in methods of treatment of disease or failure of our products to gain acceptance by patients or the medical community could negatively impact demand for our products and adversely affect revenues.
SEC original ↗Biomarin Pharmaceutical Inc. — 10-Q Quarterly report10-QAug 6, 2026
Government price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our current and future products, which would adversely affect our revenues and results of operations.
SEC original ↗Biomarin Pharmaceutical Inc. — 10-Q Quarterly report10-QAug 6, 2026
Government healthcare reform could increase our costs and adversely affect our revenues and results of operations.
SEC original ↗Biomarin Pharmaceutical Inc. — 10-Q Quarterly report10-QAug 6, 2026
Earnings deck slides
0 decks with slide viewBiomarin Pharmaceutical Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
32 documentsEarnings releases
6 documentsPresentations
1 document- Q4 2025
- BMRNDeck
Transcripts
0 documentsNo transcripts for Biomarin Pharmaceutical Inc. are held in this edition of the library.
Mentioned by
1 companyOther tracked companies whose held documents mention Biomarin Pharmaceutical Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“re subject to risks and uncertainties, actual results … …previously held various roles at BioMarin Pharmaceutical and Amgen. Internal Pipeline Updates and 2026 Outlook • ABS-201 (anti-PRLR antibody) for androgenetic alopecia: ABS-201 is an anti-PRLR ”
See also the earnings calendar for every tracked company’s next earnings date.